{"component": "definition", "props": {"groups": [{"snippet": "has the meaning specified in Section 2.1.2 hereof.", "snippet_links": [], "samples": [{"hash": "1cjvx82WzGa", "uri": "/contracts/1cjvx82WzGa#collaboration-term", "label": "Collaboration and License Agreement (Lexicon Pharmaceuticals, Inc./De)", "score": 21.353181839, "published": true}, {"hash": "26Kw3Ky2DRO", "uri": "/contracts/26Kw3Ky2DRO#collaboration-term", "label": "Collaboration and License Agreement (Lexicon Genetics Inc/Tx)", "score": 18.0, "published": true}], "size": 12, "hash": "d655018a1d6863953305f941e2ad9018", "id": 1}, {"snippet": "means the HBV Collaboration Term or the HIV Collaboration Term, as the context requires.", "snippet_links": [{"key": "hbv-collaboration-term", "type": "definition", "offset": [10, 32]}, {"key": "hiv-collaboration-term", "type": "definition", "offset": [40, 62]}, {"key": "the-context", "type": "clause", "offset": [67, 78]}], "samples": [{"hash": "a2k40dq4tuE", "uri": "/contracts/a2k40dq4tuE#collaboration-term", "label": "Research Collaboration and License Agreement (HOOKIPA Pharma Inc.)", "score": 33.1615333557, "published": true}, {"hash": "9fLy2LKWdcf", "uri": "/contracts/9fLy2LKWdcf#collaboration-term", "label": "Research Collaboration and License Agreement (HOOKIPA Pharma Inc.)", "score": 32.2087593079, "published": true}, {"hash": "5ndDYSQGzbc", "uri": "/contracts/5ndDYSQGzbc#collaboration-term", "label": "Research Collaboration and License Agreement (HOOKIPA Pharma Inc.)", "score": 31.2121829987, "published": true}], "size": 8, "hash": "ea280f04e5330e69086732f3f9e540b6", "id": 2}, {"snippet": "has the meaning set forth in Section 3.10.", "snippet_links": [], "samples": [{"hash": "UspYc1o2y4", "uri": "/contracts/UspYc1o2y4#collaboration-term", "label": "Research Collaboration, Option and License Agreement (Praxis Precision Medicines, Inc.)", "score": 31.7323741913, "published": true}, {"hash": "kMr3tDrJAey", "uri": "/contracts/kMr3tDrJAey#collaboration-term", "label": "Research Collaboration, Option and License Agreement (Praxis Precision Medicines, Inc.)", "score": 31.6557159424, "published": true}, {"hash": "eBewJuh4R2D", "uri": "/contracts/eBewJuh4R2D#collaboration-term", "label": "Research Collaboration, Option and License Agreement (Praxis Precision Medicines, Inc.)", "score": 31.5544147491, "published": true}], "size": 8, "hash": "1dc92f52d3cf6096d46084d468d002fa", "id": 3}, {"snippet": "means the time starting from the Effective Date until the earlier of (i) the Ongoing Phase 1 Trial is Completed (Reporting Purposes) and (ii) Xencor\u2019s sponsorship of the Ongoing Phase 1 Trial has been transferred to MorphoSys.", "snippet_links": [{"key": "from-the-effective-date", "type": "clause", "offset": [24, 47]}, {"key": "ongoing-phase-1-trial", "type": "definition", "offset": [77, 98]}, {"key": "reporting-purposes", "type": "clause", "offset": [113, 131]}], "samples": [{"hash": "64eggMp03C1", "uri": "/contracts/64eggMp03C1#collaboration-term", "label": "Collaboration and License Agreement (Xencor Inc)", "score": 36.1567420959, "published": true}, {"hash": "1Vt61vF2cu8", "uri": "/contracts/1Vt61vF2cu8#collaboration-term", "label": "Collaboration and License Agreement (MorphoSys AG)", "score": 29.2737846375, "published": true}, {"hash": "dVLK4x07j5O", "uri": "/contracts/dVLK4x07j5O#collaboration-term", "label": "Collaboration and License Agreement (MorphoSys AG)", "score": 29.2190284729, "published": true}], "size": 6, "hash": "ab494fddf994c487b9979092dad439e5", "id": 4}, {"snippet": "means, collectively, the R&D Term and the Post-R&D Period.", "snippet_links": [{"key": "rd-term", "type": "definition", "offset": [25, 33]}, {"key": "the-post", "type": "clause", "offset": [38, 46]}, {"key": "rd-period", "type": "definition", "offset": [47, 57]}], "samples": [{"hash": "25tl54bJL63", "uri": "/contracts/25tl54bJL63#collaboration-term", "label": "Master Collaboration and License Agreement", "score": 32.8346099854, "published": true}, {"hash": "5RZPiYInoI7", "uri": "/contracts/5RZPiYInoI7#collaboration-term", "label": "Master Collaboration and License Agreement (Moderna, Inc.)", "score": 29.8542098999, "published": true}, {"hash": "8SXfpMngZh8", "uri": "/contracts/8SXfpMngZh8#collaboration-term", "label": "Master Collaboration and License Agreement (Moderna, Inc.)", "score": 29.8295688629, "published": true}], "size": 6, "hash": "7bd5b5eae0260342ec6b0e9b108e228b", "id": 5}, {"snippet": "means the period from the Effective Date until the end of the Early Development Term hereunder.", "snippet_links": [{"key": "from-the-effective-date", "type": "clause", "offset": [17, 40]}, {"key": "early-development-term", "type": "definition", "offset": [62, 84]}], "samples": [{"hash": "gv7jiouTn3A", "uri": "/contracts/gv7jiouTn3A#collaboration-term", "label": "Product Development and Commercialization Agreement", "score": 31.3408622742, "published": true}, {"hash": "dz2xzU6E8df", "uri": "/contracts/dz2xzU6E8df#collaboration-term", "label": "Product Development and Commercialization Agreement (ChemoCentryx, Inc.)", "score": 23.0123195648, "published": true}, {"hash": "gkf8952MJbk", "uri": "/contracts/gkf8952MJbk#collaboration-term", "label": "Product Development and Commercialization Agreement (ChemoCentryx, Inc.)", "score": 22.7823410034, "published": true}], "size": 6, "hash": "0a5d959f3dd69a19d9e7f46b7a302dda", "id": 6}, {"snippet": "means the period during which the Parties will perform the Program Plan commencing on the Effective Date and terminating on the earlier of: (i) two (2) years from the Effective Date or (ii) such date as JBI has exercised its License Option for Collaboration Molecules with each of the Pharmacological Profiles. In case the Collaboration Term has terminated as described in subsection (i), the Collaboration Term may be extended for up to one (1) additional year by mutual written agreement of the Parties. In the event of termination of the Agreement prior to the end of the Collaboration Term, the Collaboration Term will be considered to have ended as of the Agreement termination date.", "snippet_links": [{"key": "period-during-which", "type": "clause", "offset": [10, 29]}, {"key": "the-parties-will", "type": "clause", "offset": [30, 46]}, {"key": "program-plan", "type": "definition", "offset": [59, 71]}, {"key": "commencing-on-the-effective-date", "type": "clause", "offset": [72, 104]}, {"key": "from-the-effective-date", "type": "clause", "offset": [158, 181]}, {"key": "license-option", "type": "definition", "offset": [225, 239]}, {"key": "in-case", "type": "clause", "offset": [311, 318]}, {"key": "the-collaboration", "type": "clause", "offset": [319, 336]}, {"key": "agreement-of-the-parties", "type": "clause", "offset": [480, 504]}, {"key": "termination-of-the-agreement", "type": "clause", "offset": [522, 550]}, {"key": "prior-to-the", "type": "clause", "offset": [551, 563]}, {"key": "agreement-termination-date", "type": "clause", "offset": [661, 687]}], "samples": [{"hash": "jOk1NMpdCx", "uri": "/contracts/jOk1NMpdCx#collaboration-term", "label": "Option and License Agreement (Scholar Rock Holding Corp)", "score": 29.3175907135, "published": true}, {"hash": "idJkMk4KX8m", "uri": "/contracts/idJkMk4KX8m#collaboration-term", "label": "Option and License Agreement (Scholar Rock Holding Corp)", "score": 29.2984256744, "published": true}, {"hash": "21QeXxOwUfr", "uri": "https://investors.scholarrock.com/static-files/455b35c6-2e47-4476-a787-780241582b46", "label": "Amendment", "score": 13.9637231827, "published": false}], "size": 6, "hash": "b9d403a526fd34687e02d1bf9c8b26a9", "id": 7}, {"snippet": "has the meaning given in Section 15.1.", "snippet_links": [{"key": "section-151", "type": "clause", "offset": [25, 37]}], "samples": [{"hash": "lFCJP7YOuE1", "uri": "/contracts/lFCJP7YOuE1#collaboration-term", "label": "Research Collaboration and Option Agreement (Recursion Pharmaceuticals, Inc.)", "score": 35.1601638794, "published": true}, {"hash": "4UOROQ1GFn7", "uri": "/contracts/4UOROQ1GFn7#collaboration-term", "label": "Research Collaboration and Option Agreement (Recursion Pharmaceuticals, Inc.)", "score": 32.2197113037, "published": true}, {"hash": "4TlgK9gTw18", "uri": "/contracts/4TlgK9gTw18#collaboration-term", "label": "Research Collaboration and Option Agreement (Recursion Pharmaceuticals, Inc.)", "score": 32.1676940918, "published": true}], "size": 6, "hash": "a22e5fac0df71a9d71906467e4185dc7", "id": 8}, {"snippet": "means the term of the collaborative research efforts carried out pursuant to this Agreement and any extension thereof.", "snippet_links": [{"key": "research-efforts", "type": "clause", "offset": [36, 52]}, {"key": "pursuant-to-this-agreement", "type": "clause", "offset": [65, 91]}], "samples": [{"hash": "fVCGWc3h7gT", "uri": "/contracts/fVCGWc3h7gT#collaboration-term", "label": "Collaboration Agreement (Isis Pharmaceuticals Inc)", "score": 21.0, "published": true}, {"hash": "1yXpT5gw3fV", "uri": "/contracts/1yXpT5gw3fV#collaboration-term", "label": "Collaboration Agreement (Isis Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "9bNvQaTA5EQ", "uri": "https://ir.ionispharma.com/static-files/27c1c7c6-e6f3-4760-84f9-1f78d017e7b9", "label": "ir.ionispharma.com", "score": 9.965092659, "published": false}], "size": 5, "hash": "49d9bb4619262f6bbc5ad94fe489ca50", "id": 9}, {"snippet": "means the Initial Term plus any extension pursuant to Section 16.2.", "snippet_links": [{"key": "initial-term", "type": "definition", "offset": [10, 22]}, {"key": "section-162", "type": "clause", "offset": [54, 66]}], "samples": [{"hash": "fpEwgO23ZgS", "uri": "/contracts/fpEwgO23ZgS#collaboration-term", "label": "Collaboration Agreement (Ignyta, Inc.)", "score": 26.3552360535, "published": true}, {"hash": "e3SlsGPyaFK", "uri": "/contracts/e3SlsGPyaFK#collaboration-term", "label": "Collaboration Agreement (Ambit Biosciences Corp)", "score": 24.2361392975, "published": true}, {"hash": "cdgtbWnsvw5", "uri": "/contracts/cdgtbWnsvw5#collaboration-term", "label": "Collaboration Agreement (Ambit Biosciences Corp)", "score": 23.967830658, "published": true}], "size": 5, "hash": "278b21fd3b12d265fc7c5af130e4ac9f", "id": 10}], "next_curs": "Cl8SWWoVc35sYXdpbnNpZGVyY29udHJhY3RzcjsLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIbY29sbGFib3JhdGlvbi10ZXJtIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"snippet": "has the meaning specified in Section 2.1.2 hereof.", "title": "Collaboration Term", "size": 231, "id": "collaboration-term", "examples": ["Prior to the expiration of the <strong>Collaboration Term</strong>, Merck may designate a Product Candidate as an \u201cElected Candidate\u201d hereunder by providing Moderna with written notice of the same (an \u201cElected Candidate Notice\u201d); provided that Merck may make no more than five (5) such designations, in the aggregate, hereunder (the \u201cElected Candidate Cap\u201d).", "Moreover, during the <strong>Collaboration Term</strong>, Xencor shall within [\u2026***\u2026] after reported to Xencor senior management, notify MorphoSys about any serious adverse events reportable to the FDA and any finding suggesting significant risk for human safety.", "During the <strong>Collaboration Term</strong>, the Parties\u2019 project teams for the XmAb5574 project (as set forth in Exhibit G) shall communicate with each other on a regular basis (at least monthly), including making promptly available all documents, data and reports relating to Licensed Antibody(ies) and/or Licensed Products (including drafts of the foregoing) to the other Party by the Party that created and/or received such documents and reports.", "During the <strong>Collaboration Term</strong>, the Joint Development Committee shall be chaired by [\u2026***\u2026] and [\u2026***\u2026] of the Joint Development Committee, [\u2026***\u2026], and the chairperson and co-chairperson of the Joint Development Committee shall be responsible for providing an agenda for each meeting and for preparing written minutes of each meeting for approval by each Party\u2019s Joint Development Committee representatives.", "During the <strong>Collaboration Term</strong>, Joint Development Committee meetings shall be held at least every [\u2026***\u2026], and may also meet more frequently as and to the extent agreed by the Parties or if reasonably required by MorphoSys.", "If such termination occurs during the <strong>Collaboration Term</strong>, then, upon MorphoSys\u2019 request, Xencor shall transfer the sponsorship for the Ongoing Phase I Trial to MorphoSys without undue delay, and MorphoSys in its sole discretion may assume responsibility for the Ongoing Phase 1 Trial.", "In the event MorphoSys enters into a Sublicense agreement after expiration of the <strong>Collaboration Term</strong>, the Joint Development Committee shall only continue to meet if the Sublicense provides for a committee between MorphoSys and its Sublicensee for discussion of development of Licensed Antibody(ies) and/or Licensed Products.", "Xencor shall disclose and/or transfer to MorphoSys copies of all Licensed Know-How created during the <strong>Collaboration Term</strong> as soon as such copies become available to Xencor, including clinical source data.", "During the <strong>Collaboration Term</strong>, Xencor shall provide MorphoSys with reasonable advance notice of any meeting or substantive telephone conference with any Regulatory Authority relating to any Licensed Antibody and/or Licensed Product.", "If MorphoSys grants any Sublicense during the <strong>Collaboration Term</strong>, then the Sublicensee may also participate in the JDC meetings, and MorphoSys is entitled, at its sole discretion, to delegate its final say on the JDC to the Sublicensee; provided, to avoid doubt, that such final say shall remain subject to all of the same limitations as set forth in Section 2.2."], "related": [["research-program-term", "Research Program Term", "Research Program Term"], ["research-term", "Research Term", "Research Term"], ["research-period", "Research Period", "Research Period"], ["research-program", "Research Program", "Research Program"], ["collaboration", "Collaboration", "Collaboration"]], "related_snippets": [], "updated": "2026-04-02T05:49:26+00:00"}, "json": true, "cursor": ""}}